Letter by Rozenbaum et al Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".
作者信息
Rozenbaum Mark H, Kemner Jason, Parasuraman Bhash
机构信息
Pfizer, Rotterdam, Zuid-Holland, the Netherlands (M.H.R.).
Pfizer, New York, NY (J.K., B.P.).
出版信息
Circulation. 2020 Oct 13;142(15):e210-e211. doi: 10.1161/CIRCULATIONAHA.120.046955. Epub 2020 Oct 12.
Abstract
摘要
相似文献
1
Letter by Rozenbaum et al Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".
Circulation. 2020 Oct 13;142(15):e210-e211. doi: 10.1161/CIRCULATIONAHA.120.046955. Epub 2020 Oct 12.
2
Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy".
Circulation. 2020 Oct 13;142(15):e212-e213. doi: 10.1161/CIRCULATIONAHA.120.049842. Epub 2020 Oct 12.
3
Letter by Baldovino et al Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
Circ Heart Fail. 2022 Jul;15(7):e009617. doi: 10.1161/CIRCHEARTFAILURE.122.009617. Epub 2022 Jun 24.
4
Response by Elliott et al to Letter Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
Circ Heart Fail. 2022 Jul;15(7):e009637. doi: 10.1161/CIRCHEARTFAILURE.122.009637. Epub 2022 Jun 24.
5
Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
Heart Fail Clin. 2024 Jul;20(3):333-341. doi: 10.1016/j.hfc.2024.03.007. Epub 2024 Apr 12.
6
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.
Circulation. 2020 Apr 14;141(15):1214-1224. doi: 10.1161/CIRCULATIONAHA.119.045093. Epub 2020 Feb 12.
7
Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Circ Heart Fail. 2015 May;8(3):519-26. doi: 10.1161/CIRCHEARTFAILURE.113.000890. Epub 2015 Apr 14.
8
Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Am J Cardiol. 2021 Jun 1;148:146-150. doi: 10.1016/j.amjcard.2021.02.035. Epub 2021 Mar 3.
9
Redefining Prognosis of Transthyretin Cardiomyopathy in the Tafamidis Era.
J Card Fail. 2022 Oct;28(10):1519-1521. doi: 10.1016/j.cardfail.2022.08.003. Epub 2022 Aug 18.
10
Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy.
Amyloid. 2024 Jun;31(2):145-147. doi: 10.1080/13506129.2023.2284108. Epub 2023 Dec 9.
Zotero 插件